Home・Lista de Ações・Edwards Lifesciences Corp

Edwards Lifesciences Corp

Fechado

SetorSaúde

89.62 0.35

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

88.38

Máximo

90.28

Indicadores-chave
By Trading Economics
Rendimento	-139M 242M
Vendas	92M 1.7B
P/E Médio do Setor	52.869 68.51
EPS	0.78
Margem de lucro	13.894
Funcionários	16,000
EBITDA	20M 520M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+15.18% upside

Dividendos
By Acuity
Próximos Ganhos	29 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.2B 51B
Abertura anterior	89.27
Fecho anterior	89.62

Sentimento de Notícias

By Acuity

35%

65%

120 / 340 Ranking em Healthcare

Edwards Lifesciences Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2026, 19:56 UTC

Edwards Lifesciences shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average.

4 de ago. de 2026, 19:36 UTC

Edwards Lifesciences shares are higher amid positive market momentum, despite a notable decline in U.S. core factory orders reflecting weakening demand across sectors.

3 de ago. de 2026, 22:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, following a notable decline that reached a session low shortly after the market opened.

31 de jul. de 2026, 19:46 UTC

Edwards Lifesciences shares are lower, reflecting broader market trends amid inflation and interest rate concerns. The stock is trading below its 20-day moving average.

30 de jul. de 2026, 22:06 UTC

Edwards Lifesciences shares are trading lower in after-market hours, reflecting ongoing weakness and uncertainty following the Federal Reserve's interest rate decision.

29 de jul. de 2026, 23:46 UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

28 de jul. de 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 de jul. de 2026, 19:41 UTC

Social Media

News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 de jul. de 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 de jul. de 2026, 23:41 UTC

News

Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 de jul. de 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 de jul. de 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 de jul. de 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Comparação entre Pares

Variação de preço

Edwards Lifesciences Corp Previsão

Preço-alvo

By TipRanks

15.18% parte superior

Previsão para 12 meses

Média 102.88 USD 15.18%

Máximo 110 USD

Mínimo 85 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Edwards Lifesciences Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para Edwards Lifesciences Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

120 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.